The National Institute for Health and Clinical Excellence (NICE) have issued their guidelines regarding the use of Infliximab to treat psoriasis. NICE have recommended Infliximab be prescribed when "the disease is very severe as defined by a total Psoriasis Area Severity Index (PASI) of 20 or more and a Dermatology Life Quality Index (DLQI) of more than 18" and "the psoriasis has failed to respond to standard systemic therapies such as ciclosporin, methotrexate or PUVA, or the person is intolerant to or has a contraindication to these treatments".

To read the guidelines, please follow the link to the NICE website. For further information on Infliximab, please click here